Editing Pfizer (section)

===2020-onwards: pandemic, corporate development, and Trump tariffs ===
====COVID-19 and vaccine development====
In March 2020, Pfizer joined the COVID-19 Therapeutics Accelerator funding vehicle to expedite development of [[Treatment and management of COVID-19|treatments against COVID-19]].<ref>{{Cite web |last=Staines |first=Richard |date=2020-03-26 |title=Pharma giants including Novartis collaborate on COVID-19 therapies |url=https://pharmaphorum.com/news/collaborate-covid19-therapies/ |url-status=live |archive-url=https://archive.today/20220118165943/https://pharmaphorum.com/news/collaborate-covid19-therapies/ |archive-date=January 18, 2022 |access-date=2022-06-06 |website=Pharmaphorum -GB }}</ref><ref>{{Cite web |title=Advancing research into accessible coronavirus treatments |url=https://www.therapeuticsaccelerator.org/ |url-status=live |archive-url=https://archive.today/20210707230649/https://www.therapeuticsaccelerator.org/ |archive-date=July 7, 2021 |access-date=2022-06-06 |website=COVID-19 Therapeutics Accelerator }}</ref> The $125 million initiative was launched by the [[Bill & Melinda Gates Foundation]] in partnership with [[Mastercard]] and [[Wellcome Trust]], with additional funding announced shortly after from [[Chan Zuckerberg Initiative]], [[Foreign, Commonwealth and Development Office|UK Foreign, Commonwealth and Development Office]] and [[Madonna]].<ref>{{Cite web |date=2020-03-10 |title=Announcing the COVID-19 Therapeutics Accelerator |url=https://www.gatesfoundation.org/ideas/articles/coronavirus-mark-suzman-therapeutics |url-status=live |archive-url=https://archive.today/20220118165008/https://www.gatesfoundation.org/ideas/articles/coronavirus-mark-suzman-therapeutics |archive-date=January 18, 2022 |access-date=2022-06-06 |website=[[Bill & Melinda Gates Foundation]] }}</ref><ref>{{Cite web |last=Au-Yeung |first=Angel |date=2020-04-03 |title=A Bill Gates-Backed Accelerator For COVID-19 Therapeutics Treatment Partners With Madonna And Mark Zuckerberg's Chan Zuckerberg Initiative |url=https://www.forbes.com/sites/angelauyeung/2020/04/03/a-bill-gates-backed-accelerator-for-covid-19-coronavirus-therapeutics-treatment-partners-with-madonna-and-mark-zuckerbergs-chan-zuckerberg-initiative/ |url-status=live |archive-url=https://archive.today/20220118165740/https://www.forbes.com/sites/angelauyeung/2020/04/03/a-bill-gates-backed-accelerator-for-covid-19-coronavirus-therapeutics-treatment-partners-with-madonna-and-mark-zuckerbergs-chan-zuckerberg-initiative/?sh=54ee18948067 |archive-date=January 18, 2022 |access-date=2022-06-06 |website=[[Forbes]] }}</ref>

The following month, the [[Foundation for the National Institutes of Health]] announced the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) public-private partnership to develop a coordinated research strategy for prioritizing and speeding up development of COVID-19 vaccines and pharmaceutical products.<ref>{{Cite web |title=Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) |url=https://www.nih.gov/research-training/medical-research-initiatives/activ |url-status=live |archive-url=https://archive.today/20220111042823/https://www.nih.gov/research-training/medical-research-initiatives/activ |archive-date=2022-01-11 |access-date=2022-06-19 |website=[[National Institutes of Health]] (NIH) }}</ref> Pfizer joined the partnership as an industry "leadership organization", and participated as a collaborator in ACTIV-led clinical trials.<ref>{{Cite web |date=2022-03-04 |author=University of Minnesota, International Network for Strategic Initiatives in Global HIV Trials (INSIGHT), University of Copenhagen, Medical Research Council, Kirby Institute, Washington D.C. Veterans Affairs Medical Center, AIDS Clinical Trials Group |title=A Multicenter, Adaptive, Randomized, Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for Hospitalized Patients With COVID-19 |url=https://clinicaltrials.gov/ct2/show/NCT04501978}}</ref><ref>{{Cite web |last=Wholley |first=David |date=2020-06-12 |title=Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) |url=https://www.bio.org/sites/default/files/2020-06/ACTIV-BIO-webinar-6-12-20-final.pdf |url-status=live |archive-url=https://web.archive.org/web/20220326054706/https://www.bio.org/sites/default/files/2020-06/ACTIV-BIO-webinar-6-12-20-final.pdf |archive-date=2022-03-26 |access-date=2022-06-18 |website=[[Biotechnology Innovation Organization]]}}</ref> CEO [[Albert Bourla]] attended the [[GAVI]] [[COVAX AMC]] 2021 Investment Opportunity Launch Event, otherwise named One World Protected, on April 15, 2021.<ref>{{Cite web |last1=U.S. Department of State |last2=USAID |date=2021-04-15 |title=The Gavi COVAX AMC Investment Opportunity Launch Event Participant List |url=https://www.gavi.org/sites/default/files/covid/covax/Investment-Opportunity-Launch-Participant-List.pdf |url-status=live |archive-url=https://web.archive.org/web/20220821050428/https://www.gavi.org/sites/default/files/covid/covax/Investment-Opportunity-Launch-Participant-List.pdf |archive-date=2022-08-21 |access-date=2022-08-21 |website=[[Gavi, the Vaccine Alliance]]|author1-link=U.S. Department of State |author2-link=USAID }}</ref>

In Canada, Pfizer endorsed the use of a [[Vaccine passports during the COVID-19 pandemic|vaccine passport]] [[mobile app]] developed by CANImmunize in order to record and track status of COVID-19 vaccination.<ref name=":3">{{Cite web |title=Partners |url=https://www.canimmunize.ca/en/partners |url-status=live |archive-url=https://web.archive.org/web/20220517111831/https://www.canimmunize.ca/en/partners |archive-date=2022-05-17 |access-date=2022-07-01 |website=CANImmunize }}</ref>

As the scale of the [[COVID-19 pandemic]] became apparent, Pfizer partnered with BioNTech to study and develop [[COVID-19]] mRNA vaccine candidates. Unlike many of its competitors, Pfizer took no initial research funds from the United States' [[Operation Warp Speed]] vaccine development program, instead choosing to invest roughly $2 billion of its own funds. Pfizer CEO Albert Bourla has said that he declined money from Operation Warp Speed to avoid government intervention, stating later that "when you get money from someone that always comes with strings. They want to see how we are going to progress, what type of moves you are going to do. They want reports. And also, I wanted to keep Pfizer out of politics, by the way."<ref>{{Cite news |last=Czachor |first=Emily |date=2020-11-09 |title=Pfizer Avoided R&D Funding From Trump's Operation Warp Speed Because of Bureaucracy, Politics |work=[[Newsweek]] |url=https://www.newsweek.com/pfizer-avoided-rd-funding-trumps-operation-warp-speed-because-bureaucracy-politics-1546110 |access-date=2021-05-18}}</ref>

In May 2020, Pfizer began testing four different [[COVID-19 vaccine]] variations using [[lipid nanoparticle]] technology provided by Canadian biotechnology company [[Acuitas Therapeutics]].<ref name=":22">{{Cite web |last=Bianchini |first=Elisabetta |date=2020-11-10 |title=Acuitas Therapeutics: The Canadian technology that the Pfizer and BioNTech COVID-19 vaccine 'can't work without' |url=https://ca.news.yahoo.com/covid19-vaccine-coronavirus-canada-acuitas-therapeutics-pfizer-biontech-211410040.html |url-status=live |archive-url=https://web.archive.org/web/20220930214712/https://ca.news.yahoo.com/covid19-vaccine-coronavirus-canada-acuitas-therapeutics-pfizer-biontech-211410040.html |archive-date=2022-09-30 |access-date=2022-09-30 |website=[[Yahoo! News]] -CA}}</ref> Vaccines were injected into the first human participants in the U.S. in early May. In July 2020, Pfizer and BioNTech announced that two of the partners' four [[Messenger RNA|mRNA]] vaccine candidates had won fast track designation from the [[Food and Drug Administration|FDA]].<ref>{{Cite web |last=DeArment |first=Alaric |date=2020-07-13 |title=Pfizer, BioNTech get fast-track from FDA for Covid-19 vaccines |url=https://medcitynews.com/2020/07/pfizer-biontech-get-fast-track-from-fda-for-covid-19-vaccines/ |access-date=2020-07-15 |website=MedCity News}}</ref> The company began Phase{{spaces}}II-III testing on 30,000 people in the last week of July 2020 and was slated to be paid $1.95{{spaces}}billion for 100{{nbsp}}million doses of the vaccine by the US government.<ref>{{Cite news |title=Pfizer Beats Forecasts as Vaccine Trial Enters Final Stage |url=https://www.wsj.com/articles/pfizer-sales-fall-as-company-races-toward-covid-19-vaccine-11595936314 |website=The Wall Street Journal |date=July 29, 2020}}</ref> In September 2020, Pfizer and BioNTech announced that they had completed talks with the European Commission to provide an initial 200{{nbsp}}million vaccine doses to the EU, with the option to supply another 100{{nbsp}}million doses at a later date.<ref>{{Cite news |last=Kilgore |first=Tomi |title=Pfizer, BioNTech conclude talks over supplying EU with SARS-CoV-2 vaccine candidate |url=https://www.marketwatch.com/story/pfizer-biontech-conclude-talks-over-supplying-eu-with-sars-cov-2-vaccine-candidate-2020-09-09 |access-date=2020-09-10 |website=MarketWatch}}</ref>

On November 9, 2020, Pfizer announced that BioNTech's COVID-19 vaccine, tested on 43,500 people, was found to be 90% effective at preventing symptomatic COVID-19.<ref>{{Cite news |date=November 9, 2020 |title=Covid vaccine: First 'milestone' vaccine offers 90% protection |work=[[BBC News]] |url=https://www.bbc.com/news/health-54873105}}</ref> The efficacy was updated to 95% a week later.<ref name=":1">{{Cite web |last=Kounang |first=Nadia |date=9 November 2020 |title=Pfizer and BioNTech say final analysis shows coronavirus vaccine is 95% effective with no safety concerns |url=https://www.cnn.com/2020/11/18/health/pfizer-coronavirus-vaccine-safety/index.html |access-date=9 November 2020 |website=CNN}}</ref> Akiko Iwasaki, an immunologist interviewed by ''The New York Times'', described the efficacy figure as "really a spectacular number."<ref>{{Cite news |last1=Thomas |first1=Katie |last2=Gelles |first2=David |last3=Zimmer |first3=Carl |date=2020-11-09 |title=Pfizer's Early Data Shows Vaccine Is More Than 90% Effective |work=The New York Times |url=https://www.nytimes.com/2020/11/09/health/covid-vaccine-pfizer.html |access-date=2021-05-18 |issn=0362-4331}}</ref> The announcement made Pfizer and BioNTech the first companies to develop and test a working vaccine for COVID-19.<ref name=":1" />

Over the following month and a half, regulators in various countries approved Pfizer's vaccine for emergency use.<ref>{{Cite web |last=Roberts |first=Michelle |date=2 December 2020 |title=Covid-19: Pfizer/BioNTech vaccine judged safe for use in UK |url=https://www.bbc.com/news/health-55145696 |access-date=2 December 2020 |website=[[BBC News]]}}</ref><ref name="Bahrain Approves Covid-19 Vaccine (Al Jazeera)">{{Cite news |date=4 December 2020 |title=Bahrain becomes second country to approve Pfizer COVID-19 vaccine |publisher=Al Jazeera |url=https://www.aljazeera.com/news/2020/12/4/bahrain-becomes-second-country-to-approve-pfizer-covid-19-vaccine |access-date=11 December 2020}}</ref><ref>{{Cite news |last=Austen |first=Ian |date=9 December 2020 |title=Canada Approves Vaccine and Could Start Shots Next Week |work=The New York Times |url=https://www.nytimes.com/2020/12/09/world/americas/canada-vaccine-approve.html |url-access=subscription |access-date=11 December 2020 |url-status=live |archive-url=https://web.archive.org/web/20201211000426/https://www.nytimes.com/2020/12/09/world/americas/canada-vaccine-approve.html |archive-date=11 December 2020 }}</ref><ref>{{Cite news |date=11 December 2020 |title=Saudi Arabia approves Pfizer COVID-19 vaccine as Bahrain plans to give the public free shots |work=KTLA |url=https://ktla.com/news/nationworld/saudi-arabia-approves-pfizer-covid-19-vaccine-as-bahrain-plans-to-give-the-public-free-shots/ |access-date=11 December 2020}}</ref><ref>{{Cite news |last=Steenhuysen |first=Manas Mishra, Julie |date=11 December 2020 |title=U.S. FDA advisers overwhelmingly back authorizing Pfizer–BioNTech COVID-19 vaccine |work=Reuters |url=https://www.reuters.com/article/health-coronavirus-pfizer-vaccine/us-fda-advisers-wrestle-with-ethical-issues-linked-to-authorizing-pfizers-covid-19-vaccine-idUSKBN28K1O5 |access-date=11 December 2020}}</ref><ref>{{Cite news |last1=Thomas |first1=Katie |last2=LaFraniere |first2=Sharon |last3=Weiland |first3=Noah |last4=Goodnough |first4=Abby |last5=Haberman |first5=Maggie |date=2020-12-12 |title=F.D.A. Clears Pfizer Vaccine, and Millions of Doses Will Be Shipped Right Away |work=The New York Times |url=https://www.nytimes.com/2020/12/11/health/pfizer-vaccine-authorized.html |access-date=2020-12-12 |issn=0362-4331}}</ref><ref>{{Cite news |last=Abdullah |first=Zhaki |title=Pfizer–BioNTech COVID-19 vaccine approved by Singapore, first shipment expected by end-December |url=https://www.channelnewsasia.com/news/singapore/singapore-approves-pfizer-biontech-covid-19-vaccine-phase-3-13769570 |date=December 14, 2020 |website=CNA |access-date=January 20, 2021 |archive-date=February 4, 2021 |archive-url=https://web.archive.org/web/20210204082015/https://www.channelnewsasia.com/news/singapore/singapore-approves-pfizer-biontech-covid-19-vaccine-phase-3-13769570 |url-status=dead }}</ref><ref>{{cite news |url=https://www.ema.europa.eu/en/news/ema-recommends-first-covid-19-vaccine-authorisation-eu |title=EMA recommends first COVID-19 vaccine for authorisation in the EU |website=[[Europa (web portal)|Europa]] |date=December 21, 2020}}</ref>

==== Controversy ====
In February 2021, after a year long investigation relying on unnamed officials, Pfizer was accused by [[The Bureau of Investigative Journalism]] (TBIJ) of employing "high-level bullying" against at least two [[Latin America]]n countries during negotiations to acquire COVID-19 vaccines, including requesting that the countries put sovereign assets as [[Collateral (finance)|collateral]] for payments.<ref name="bullied">{{Cite news |title=Investigation: Drugmaker 'bullied' Latin American nations |url=https://www.aljazeera.com/news/2021/3/11/investigation-pfizer-bullied-latin-american-nations |website=[[Al Jazeera English]] |date=March 11, 2021}}</ref> According to TBIJ, these negotiation tactics resulted in a months long delay in Pfizer reaching a vaccine agreement with one country and a complete failure to reach agreements with two other countries, including [[Argentina]] and Brazil.<ref name="bullied"/>

In November 2021, TBMJ published an article after obtaining information from a [[whistleblower]] from the Ventavia Research Group. Ventavia was hired by Pfizer as a research subcontractor. A regional director (whistleblower) who was employed at Ventavia Research Group has told ''The BMJ'' that the company falsified data, unblinded patients, employed inadequately trained vaccinators, and was slow to follow up on adverse events reported in [[Pfizer–BioNTech COVID-19 vaccine#Clinical trials|Pfizer's pivotal phase III trial]]. The regional director, Brook Jackson, emailed a complaint to the US [[Food and Drug Administration]] (FDA). Ventavia fired her later the same day.<ref>{{cite news |last1=Thacker |first1=Paul |title=Covid-19: Researcher blows the whistle on data integrity issues in Pfizer's vaccine trial |url=https://www.bmj.com/content/375/bmj.n2635 |access-date=2 November 2021 |publisher=thebmj}}</ref> The [[European Medicines Agency]] (EMA) stated in a response to the [[European Parliament]], that "the deficiencies identified do not jeopardize the quality and integrity of the data from the main Comirnaty trial and have no impact on the benefit-risk assessment or on the conclusions on the safety, effectiveness and quality of the vaccine".<ref>{{Cite web |url=https://www.ema.europa.eu/en/documents/other/ema-reply-letter-members-european-parliament-ms-m-rivasi-mr-p-pedicini-ms-t-metz-concerning-covid-19_en.pdf |title=Reply letter on the Integrity of clinical data, additional clinical trials and studies, pharmacovigilance and mRNA COVID-19 vaccine safety |author=[[European Medicines Agency]] |date=3 December 2021 |access-date=2 February 2022}}</ref> ''[[Science-Based Medicine]]'' emphasized that Ventavia oversaw just three of the 153 clinical sites involved with Pfizer's trial and "a small fraction (~1,000 by the time the whistleblower was fired) of the trial's over ~44,000 subjects."<ref>{{Cite news |last=Gorski |first=David |author-link=David Gorski |date=November 8, 2021 |title=What the heck happened to The BMJ? |work=Science-Based Medicine |url=https://sciencebasedmedicine.org/what-the-heck-happened-to-the-bmj/ |access-date=May 16, 2023}}</ref>

On 10 October 2022, during a session of the [[European Parliament]]'s Special Committee on the COVID-19 Pandemic, Pfizer executive Janine Small testified that the company had not evaluated their [[Pfizer–BioNTech COVID-19 vaccine|COVID-19 vaccine]] for its ability to reduce transmission of the [[SARS-CoV-2]] virus prior to its release to the general public.<ref>{{Cite web |date=2022-10-10 |title=Special Committee on COVID-19 pandemic |url=https://multimedia.europarl.europa.eu/en/webstreaming/special-committee-on-covid-19-pandemic_20221010-1430-COMMITTEE-COVI |url-status=live |archive-url=https://web.archive.org/web/20221014010053/https://multimedia.europarl.europa.eu/en/webstreaming/special-committee-on-covid-19-pandemic_20221010-1430-COMMITTEE-COVI |archive-date=2022-10-14 |access-date=2022-10-14 |website=[[European Parliament]] Multimedia Centre }}</ref><ref>{{Cite web |last=TN World Desk |date=2022-10-13 |title=Pfizer admits it did not know whether its Covid vaccine prevented transmission of virus when rollout began |url=https://www.timesnownews.com/world/pfizer-admits-it-did-not-know-its-covid-vaccine-prevented-transmission-of-virus-when-rollout-began-article-94836651 |url-status=live |archive-url=https://archive.today/20221013205522/https://www.timesnownews.com/world/pfizer-admits-it-did-not-know-its-covid-vaccine-prevented-transmission-of-virus-when-rollout-began-article-94836651 |archive-date=2022-10-13 |access-date=2022-10-14 |website=[[TimesNow]] }}</ref> Dutch MEP [[Rob Roos]] described the admission as "scandalous".<ref>{{Cite web |last=Chung |first=Frank |date=2022-10-13 |title=Pfizer did not know whether Covid vaccine stopped transmission before rollout, executive admits |url=https://www.news.com.au/technology/science/human-body/pfizer-did-not-know-whether-covid-vaccine-stopped-transmission-before-rollout-executive-admits/news-story/f307f28f794e173ac017a62784fec414 |url-status=live |archive-url=https://web.archive.org/web/20221014110736/https://www.news.com.au/technology/science/human-body/pfizer-did-not-know-whether-covid-vaccine-stopped-transmission-before-rollout-executive-admits/news-story/f307f28f794e173ac017a62784fec414 |archive-date=2022-10-14 |access-date=2022-10-14 |website=[[News.com.au]]}}</ref> CEO [[Albert Bourla]] was slated to attend, but withdrew.<ref>{{Cite web |last=Bauer-Babef |first=Clara |date=2022-10-12 |title=Pfizer remains discreet about COVID vaccine purchase contracts |url=https://www.euractiv.com/section/coronavirus/news/pfizer-remains-discreet-about-covid-vaccine-purchase-contracts/ |url-status=live |archive-url=https://web.archive.org/web/20221013183554/https://www.euractiv.com/section/coronavirus/news/pfizer-remains-discreet-about-covid-vaccine-purchase-contracts/ |archive-date=2022-10-13 |access-date=2022-10-14 |website=[[Euractiv]] -GB}}</ref> Roos' statements in turn have been described as "misleading".<ref>{{Cite web |date=October 18, 2022 |first=Flora |last=Teoh |title=Scientific studies show that the Pfizer-BioNTech COVID-19 vaccine reduces transmission; claim by Rob Roos is misleading |url=https://science.feedback.org/review/scientific-studies-show-pfizer-biontech-covid-19-vaccine-reduces-transmission-claim-rob-roos-misleading/ |url-status=live |archive-url=https://web.archive.org/web/20240916075734/https://science.feedback.org/review/scientific-studies-show-pfizer-biontech-covid-19-vaccine-reduces-transmission-claim-rob-roos-misleading/ |archive-date=September 16, 2024 |access-date=September 16, 2024 |website=Science Feedback |publisher=Health Feedback -GB}}</ref>

==== Development of oral antivirals ====
In November 2021, Pfizer launched a new COVID-19 oral antivirus treatment known as [[Nirmatrelvir/ritonavir|Paxlovid]]. In January 2022, the Pfizer CEO [[Albert Bourla]] confirmed that the trial results of a fourth dose were pending until March 2022. He said that the firm was setting up a collaboration to develop an anti-COVID pill treatment along with a French company, [[Novasep]]. He also said the COVID vaccine was "safe and efficient" for children.<ref>{{Cite web |url=https://www.israelnationalnews.com/news/320624 |title=Pfizer CEO: Current wave will be last with so many restrictions |access-date=17 January 2021 |website=[[Israel National News]]}}</ref><ref>{{Cite web |url=https://www.livemint.com/companies/news/pfizer-ceo-shares-some-good-news-on-covid-but-cautions-virus-could-circulate-for-years-11642405004050.html |title=Pfizer CEO shares some good news on covid but cautions virus could circulate for years |access-date=17 January 2021 |website=[[Mint (newspaper)|Mint]]}}</ref> In May 2022, reports emerged of patients experiencing "rebound" symptoms after completing a five-day course of Paxlovid.<ref>{{Cite news |last=Hopkins |first=Jared S. |date=2022-05-10 |title=Some Covid-19 Patients Relapse After Taking Paxlovid, Puzzling Doctors |work=[[The Wall Street Journal]] |url=https://www.wsj.com/articles/some-covid-19-patients-relapse-after-taking-paxlovid-puzzling-doctors-11652186194 |access-date=2022-05-16 |issn=0099-9660}}</ref> The FDA responded by announcing they had performed additional analyses of the drug's clinical trial data, and decided against changing its recommendations.<ref>{{Cite journal |last=Farley |first=John |date=2022-05-04 |title=FDA Updates on Paxlovid for Health Care Providers |url=https://www.fda.gov/drugs/news-events-human-drugs/fda-updates-paxlovid-health-care-providers |journal=[[Food and Drug Administration]] }}</ref> U.S. President [[Joe Biden]] and Dr. [[Anthony Fauci]] were both reported to experience this rebound syndrome in the months that followed, while continuing to recommend the drug for those who may benefit from it.<ref>{{Cite web |last=Samuels |first=Fionna M. D. |date=2022-08-08 |title=What Is Paxlovid Rebound, and How Common Is It? |url=https://www.scientificamerican.com/article/what-is-paxlovid-rebound-and-how-common-is-it/ |url-status=live |archive-url=https://archive.today/20220818063840/https://www.scientificamerican.com/article/what-is-paxlovid-rebound-and-how-common-is-it/ |archive-date=2022-08-18 |access-date=2022-08-22 |website=[[Scientific American]] }}</ref>

==== Corporate developments and acquisitions ====
In September 2020, the company acquired a 9.9% stake in CStone Pharmaceuticals for $200{{nbsp}}million (HK$1.55{{nbsp}}billion), helping to commercialise its anti-[[PD-L1]] monoclonal antibody, CS1001.<ref>{{Cite news |title=Pfizer to buy 9.9% of CStone for $200 million, eyes collaboration |url=https://www.reuters.com/article/us-cstone-pfizer/pfizer-to-buy-9-9-of-cstone-for-200-million-eyes-collaboration-idUKKBN26L01D |work=[[Reuters]] |date=September 29, 2020}}</ref> In October 2020, the company acquired Arixa Pharmaceuticals.<ref>{{Cite magazine |url=https://www.fiercebiotech.com/biotech/pfizer-snaps-up-antibiotics-maker-arixa-and-its-oral-avycaz-follow-up |title=Biotech Pfizer snaps up antibiotics maker Arixa and its oral Avycaz follow-up |first=Amirah |last=Al Idrus |magazine=Fierce Pharma |date=October 22, 2020}}</ref> In November 2020, using a [[Reverse Morris Trust]] structure, Pfizer merged its off-patent branded and [[generic drug]] business, known as Upjohn, with [[Mylan]] to form [[Viatris]], owned 57% by Pfizer shareholders.<ref>{{Cite news |url=https://www.nasdaq.com/articles/pfizer-completes-combination-of-upjohn-and-mylan-viatris-to-begin-trading-on-nov.-17-2020 |title=Pfizer Completes Combination Of Upjohn And Mylan; Viatris To Begin Trading On Nov. 17 |work=[[Nasdaq]] |date=November 16, 2020}}</ref><ref>{{Cite news |url=https://www.post-gazette.com/business/healthcare-business/2020/11/16/Mylan-merger-Upjohn-Viatris-bresch-coury-Pfizer-cost-cuts-generic-drugs/stories/202011160111 |title=Mylan completes merger with Upjohn to form Viatris |first=Patricia |last=Sabatini |work=[[Pittsburgh Post-Gazette]] |date=November 16, 2020}}</ref>

On January 5, 2021, Pfizer introduced a new [[logo]].<ref>{{Cite news |last=Bruell |first=Alexandra |title=Pfizer Introduces New Logo Playing Up Role in Drug Creation |url=https://www.wsj.com/articles/pfizer-introduces-new-logo-playing-up-role-in-drug-creation-11609844400 |work=[[The Wall Street Journal]] |date=January 5, 2021 |issn=0099-9660 |url-access=subscription}}</ref> In April 2021, Pfizer acquired Amplyx Pharmaceuticals and its anti-fungal compound [[fosmanogepix]] (APX001).<ref>{{cite magazine |url=https://www.fiercebiotech.com/biotech/pfizer-buys-amplyx-to-grow-infectious-disease-pipeline |title=Pfizer buys Amplyx to grow infectious disease pipeline |first=Nick Paul |last=Taylor |magazine=Fierce Pharma |date=April 28, 2021}}</ref><ref>{{Cite news |url=https://www.sandiegouniontribune.com/2021/04/28/pfizer-acquires-fungus-fighting-san-diego-biotech |title=Pfizer acquires fungus-fighting San Diego biotech |first=Jonathan |last=Wosen |work=[[The San Diego Union-Tribune]] |date=April 28, 2021}}</ref> In August, the company announced it would acquire Trillium Therapeutics Inc and its immuno-oncology portfolio for $2.3 billion.<ref>{{Cite news |url=https://www.reuters.com/business/pfizer-buy-trillium-therapeutics-226-bln-deal-2021-08-23/ |title=Pfizer to buy cancer drug developer Trillium in $2.3 BLN deal |newspaper=Reuters |date=August 23, 2021}}</ref><ref>{{Cite web |url=https://www.biospace.com/article/releases/pfizer-to-acquire-trillium-therapeutics-inc-/?s=79 |title=Pfizer to Acquire Trillium Therapeutics Inc|date=August 23, 2021 }}</ref>

In March 2022, the company acquired [[Arena Pharmaceuticals]] for $6.7 billion in cash.<ref>{{Cite press release | url=https://www.businesswire.com/news/home/20220310005794/en/Pfizer-Completes-Acquisition-of-Arena-Pharmaceuticals | title=Pfizer Completes Acquisition of Arena Pharmaceuticals | publisher=[[Business Wire]] | date=March 11, 2022}}</ref><ref>{{cite web |title=Pfizer bets on Arena's promising bowel disease treatment in $6.7 bln deal |url=https://www.reuters.com/markets/deals/pfizer-acquire-arena-pharmaceuticals-67-bln-deal-2021-12-13 |work=[[Reuters]] |date=December 13, 2021 |access-date=December 13, 2021}}</ref><ref>{{cite web |title=Pfizer to Acquire Arena Pharmaceuticals in $6.7 Billion Deal |url=https://www.wsj.com/articles/pfizer-to-acquire-arena-pharmaceuticals-in-6-7-billion-deal-11639414813 |work=[[The Wall Street Journal]] |last=Walker |first=Joseph |date=December 13, 2021 |access-date=December 13, 2021}}</ref> In June 2022, the company acquired ReViral Ltd, for up to $525 million, gaining access to experimental drugs used to combat [[respiratory syncytial virus]] infections.<ref>{{Cite news | url=https://www.reuters.com/business/healthcare-pharmaceuticals/pfizer-buy-rsv-drug-developer-reviral-up-525-mln-2022-04-07/ | title=Pfizer boosts respiratory drug portfolio with ReViral purchase | newspaper=Reuters | date=April 7, 2022 | last1=Satija | first1=Bhanvi }}</ref><ref>{{Cite web |date=2022-06-10 |title=Pfizer acquires biopharma firm ReViral for up to $525m |url=https://www.pharmaceutical-technology.com/news/pfizer-acquires-biopharma-reviral/ |access-date=2022-06-10 |website=Pharmaceutical Technology }}</ref> In October 2022, the company acquired Biohaven Pharma and its [[calcitonin gene-related peptide]] programs for $11.6 billion.<ref>{{cite web | url=https://www.biospace.com/article/releases/pfizer-completes-acquisition-of-biohaven-pharmaceuticals/?s=110 | title=Pfizer Completes Acquisition of Biohaven Pharmaceuticals | date=October 3, 2022 }}</ref><ref>{{cite press release | url=https://www.businesswire.com/news/home/20220510005676/en/ | title=Pfizer to Acquire Biohaven Pharmaceuticals | date=May 10, 2022}}</ref><ref>{{cite web | url=https://www.biospace.com/article/pfizer-drops-a-cool-11-6-billion-on-migraine-leader-biohaven-/?s=79 | title=Pfizer Drops a Cool $11.6B on Migraine Leader Biohaven | date=May 10, 2022 }}</ref> It also acquired Global Blood Therapeutics for $5.4 billion, boosting Pfizer's rare disease business.<ref>{{Cite press release | url=https://www.businesswire.com/news/home/20221004006158/en/Pfizer-Completes-Acquisition-of-Global-Blood-Therapeutics%C2%A0 | title=Pfizer Completes Acquisition of Global Blood Therapeutics | publisher=[[Business Wire]] | date=October 5, 2022}}</ref><ref>{{Cite news |last=Rockoff |first=Jonathan D. |date=2022-08-08 |title=Pfizer Agrees to $5.4 Billion Deal for Global Blood Therapeutics |work=[[The Wall Street Journal]] |url=https://www.wsj.com/articles/pfizer-reaches-5-4-billion-deal-for-global-blood-therapeutics-11659954601 |access-date=2022-08-08 |issn=0099-9660}}</ref><ref>{{Cite news |date=2022-08-08 |title=Flush with cash, Pfizer buys Global Blood Therapeutics in $5.4 billion deal |work=Reuters |url=https://www.reuters.com/business/healthcare-pharmaceuticals/pfizer-buy-global-blood-therapeutics-54-bln-deal-2022-08-08/ |access-date=2022-08-08}}</ref>

In April 2023, Pfizer moved its world headquarters from [[42nd Street (Manhattan)|42nd Street]] in [[Midtown Manhattan]] to the Spiral at [[Hudson Yards (development)|Hudson Yards]].<ref>{{cite news |url=https://www.crainsnewyork.com/health-care/pfizer-opens-global-headquarters-hudson-yards-empty-offices-reach-pandemic-levels |last1=D'Ambrosio |first1=Amanda |title=Pfizer opens global headquarters in Hudson Yards as empty offices reach pandemic levels |work=[[Crain Communications]] |date=April 3, 2023}}</ref><ref>{{cite magazine |url=https://www.fiercepharma.com/pharma/pfizer-moves-west-side-settling-down-swanky-new-digs-hudson-yards-spiral-skyscraper |last1=Liu |first1=Angus |last2=Kansteiner |first2=Fraiser |title=Pfizer moves on up to the West Side, establishing new nerve center at Hudson Yards' Spiral skyscraper |magazine=Fierce Pharma |date=April 4, 2023}}</ref>

In December 2023, the company acquired [[Seagen]], a pioneer of [[antibody–drug conjugate]]s for the treatment of cancer, for $43{{nbsp}}billion.<ref>{{cite news |last=Mishra |first=Manas |date=2022-03-13 |title=Pfizer signs $43 bln Seagen deal in cancer drug push |url=https://www.reuters.com/markets/deals/pfizer-buy-seagen-deal-valued-43-billion-2023-03-13/ |publisher=[[Reuters]]}}</ref><ref>{{Cite press release | url=https://www.businesswire.com/news/home/20231213759493/en/Pfizer-Completes-Acquisition-of-Seagen | title=Pfizer Completes Acquisition of Seagen | publisher=[[Business Wire]] | date=December 14, 2023}}</ref>

On Sept 30, 2024, Pfizer announced its intentions to sell 540 million Haleon shares whose worth is about  £2.1 billion ($2.8 billion)  according to Bloomberg calculations.<ref>{{Cite web |date=October 1, 2024 |title=Pfizer to further reduce stake in Haleon, offers to sell 540 million share |url=https://www.business-standard.com/world-news/pfizer-to-further-reduce-stake-in-haleon-offers-to-sell-540-million-share-124100101515_1.html}}</ref>

In the third quarter of 2024, Pfizer reported $17.7 billion in revenue, a 32% year-over-year increase, driven by [[Nirmatrelvir/ritonavir|Paxlovid]] ($2.7 billion) and [[Pfizer–BioNTech COVID-19 vaccine|Comirnaty]] ($1.4 billion). Excluding COVID-19 products, core revenue grew 14% to $13.6 billion, led by [[Tafamidis|Vyndaqel]] sales (up 63%) and $854 million from legacy Seagen products. The company raised its 2024 revenue guidance to $61.0–$64.0 billion and adjusted diluted earnings per share to $2.75–$2.95. Pfizer remains on track for $5.5 billion in cost savings, with $4 billion expected by 2024 and $1.5 billion by 2027. Reported diluted earnings per share was $0.78, and adjusted diluted earnings per share was $1.06. The company ranks 69th on the [[Fortune 500|''Fortune'' 500]] of the same year.<ref>{{Cite web |date=2024-10-29 |title=Pfizer Delivers Strong Third-Quarter 2024 Financial Results and Raises 2024 Guidance |url=https://insights.pfizer.com/q324earnings/ |access-date=2025-04-02 |website=Pfizer Investor Insights |language=en-US}}</ref>